160 related articles for article (PubMed ID: 21707241)
1. Differential expression of a novel voltage gated potassium channel--Kv 1.5 in astrocytomas and its impact on prognosis in glioblastoma.
Arvind S; Arivazhagan A; Santosh V; Chandramouli BA
Br J Neurosurg; 2012 Feb; 26(1):16-20. PubMed ID: 21707241
[TBL] [Abstract][Full Text] [Related]
2. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753
[TBL] [Abstract][Full Text] [Related]
3. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
4. Geminin: a good prognostic factor in high-grade astrocytic brain tumors.
Shrestha P; Saito T; Hama S; Arifin MT; Kajiwara Y; Yamasaki F; Hidaka T; Sugiyama K; Kurisu K
Cancer; 2007 Mar; 109(5):949-56. PubMed ID: 17262828
[TBL] [Abstract][Full Text] [Related]
5. Expression of voltage-gated potassium channels Kv1.3 and Kv1.5 in human gliomas.
Preussat K; Beetz C; Schrey M; Kraft R; Wölfl S; Kalff R; Patt S
Neurosci Lett; 2003 Jul; 346(1-2):33-6. PubMed ID: 12850541
[TBL] [Abstract][Full Text] [Related]
6. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
[TBL] [Abstract][Full Text] [Related]
9. Relationship between CacyBP/SIP expression and prognosis in astrocytoma.
Zhao W; Wang C; Wang J; Ge A; Li Y; Li W; Lu Y
J Clin Neurosci; 2011 Sep; 18(9):1240-4. PubMed ID: 21764585
[TBL] [Abstract][Full Text] [Related]
10. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
11. Expression of diagnostic neuronal markers and outcome in glioblastoma.
Donev K; Scheithauer BW; Rodriguez FJ; Jenkins S
Neuropathol Appl Neurobiol; 2010 Aug; 36(5):411-21. PubMed ID: 20298476
[TBL] [Abstract][Full Text] [Related]
12. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
13. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
14. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma.
Somasundaram K; Reddy SP; Vinnakota K; Britto R; Subbarayan M; Nambiar S; Hebbar A; Samuel C; Shetty M; Sreepathi HK; Santosh V; Hegde AS; Hegde S; Kondaiah P; Rao MR
Oncogene; 2005 Oct; 24(47):7073-83. PubMed ID: 16103883
[TBL] [Abstract][Full Text] [Related]
16. Spinal cord malignant astrocytomas. Clinicopathologic features in 36 cases.
Santi M; Mena H; Wong K; Koeller K; Olsen C; Rushing EJ
Cancer; 2003 Aug; 98(3):554-61. PubMed ID: 12879473
[TBL] [Abstract][Full Text] [Related]
17. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of chemokine receptor CXCR3 and its ligand CXCL10 in low-grade astrocytomas and glioblastoma multiforme: A tissue microarray-based comparison.
Sharma I; Siraj F; Sharma KC; Singh A
J Cancer Res Ther; 2016; 12(2):793-7. PubMed ID: 27461653
[TBL] [Abstract][Full Text] [Related]
19. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma.
Mizumatsu S; Tamiya T; Ono Y; Abe T; Matsumoto K; Furuta T; Ohmoto T
Clin Cancer Res; 1999 Mar; 5(3):551-7. PubMed ID: 10100706
[TBL] [Abstract][Full Text] [Related]
20. Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma.
Söling A; Sackewitz M; Volkmar M; Schaarschmidt D; Jacob R; Holzhausen HJ; Rainov NG
Clin Cancer Res; 2005 Jan; 11(1):249-58. PubMed ID: 15671553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
